Tag Archives: China

Program unveiled for third annual BIO Convention in China

biochina-flag-btn

The third annual BIO Convention in China is just around the corner, taking place Nov. 11-13 in Beijing, China. We’ve got an exciting mix of speakers, panels, and workshops scheduled. Keynote speakers include Washington Governor Jay Inslee, U.S. Ambassador to China Gary Locke, CFDA Assistant Minister Bian Zhenjia, and China Center for Pharmaceutical Exchange Director General Zhao Yajun, as well as BIO’s own President and CEO James Greenwood. If you haven’t, be sure to take Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

Washington Gov. Jay Inslee to Keynote BIO Convention in China

Gov_Inslee_115x76

Next month, BIO will be hosting our 3rd Annual BIO Convention in China, November 11-13. We are very pleased that Washington Governor Jay Inslee will be joining us as our keynote speaker on November 12. “China is a rapidly growing market for America’s innovative biotechnology companies, including those in Washington State. As this market continues to expand, it will be increasingly important to develop collaborative relationships with the Chinese government, companies, and academic institutions. The BIO Convention Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

2013 BIO Convention in China Facilitates East-West Partnering in Biotech

biochina-flag-btn

Now in its third year, the BIO Convention in China will be held November 11-13, 2013 in Beijing, China. A sister event to the BIO International Convention, BIO China will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities in China, where the Rx market is poised to grow to $315 billion in 2020. For Western companies and investors looking to capitalize Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

Chinese In-Licensing Continues to Strengthen

Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are outpacing other forms of biotech deal-making in 2013. In fact, the number of in-licensing deals announced so far this year is more than the combined number of 2012 deals in out-licensing, JV/Alliance and M&A, according to BIO’s Industry Analysis research and GBI. This deal-making momentum bodes well for small and medium-sized biotech companies that have early-stage compounds under development in the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

China’s Biotech Innovators

As the Chinese government implements policies aimed at increasing innovation in the life sciences industry, a new breed of domestic Chinese companies are structuring their corporate infrastructure to amplify innovation. Three themes are emerging from these innovative Chinese companies: the development of new business models, partnering with Western entities, and placing Chinese citizens at the helm that have advanced degrees and industrial experience from the West. As an example, consider the management and business model Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,